Sb-728 clinical trials

Pharmacokinetic Enhancer cobicistat. Pharmacokinetic Enhancer ritonavir. Post-attachment Inhibitor. Protease Inhibitors PIs.

Protease Inhibitor atazanavir. Protease Inhibitor darunavir. Protease Inhibitor lopinavir. Skin and Mucus Membrane Products.

Therapeutic Vaccines. Bacterial Enteric Infections. Mucocutaneous Candidiasis. Cytomegalovirus Disease. Disseminated Mycobacterium avium Complex Disease.

Toxoplasma gondii Encephalitis. Human Herpesvirus-8 Diseases. Herpes Simplex Virus Disease. Varicella-Zoster Virus Diseases.

Hepatitis B Virus Infection. Hepatitis C Virus Infection. Herpes Zoster. Pneumocystis Pneumonia. Penicilliosis marneffei. Drug information Audio. Your browser does not support the audio element. Other Names:. Drug Class:. Registry Number:. Phase of Development:. What is SBT? How does SBT work? This study is currently recruiting participants.

This study does not involve any treatment. This study has been enrolling by invitation. What side effects might SBT cause? Where can I get more information about clinical trials studying SBT?

Accessed December 15, Treatment Action Group website. Research toward a cure trials. Newer gene editing technologies toward HIV gene therapy. Sangamo Therapeutics. In: ClinicalTrials. Antimalarial Aminoquinoline. Antimalarial Dihydrofolate Reductase Inhibitor. Antimycobacterial Cyclic Peptide. Antimycobacterial Rifamycins. Antiviral Interferon Alpha. Antiviral Nucleoside Analog. Attachment Inhibitor. Broadly Neutralizing Antibodies. Capsid Inhibitors. CCR5 Antagonist. CD4 Attachment Inhibitor.

Combination Drugs. Fusion Inhibitor. Gene Therapy Products. Immune Globulins. Immune Modulators. Integrase Inhibitors. Integrase Strand Transfer Inhibitor bictegravir. Integrase Strand Transfer Inhibitor cabotegravir. Integrase Strand Transfer Inhibitor dolutegravir. Integrase Strand Transfer Inhibitor elvitegravir. Latency-Reversing Agents. Maturation Inhibitors. Non-Nucleoside Reverse Transcriptase Inhibitor doravirine. Non-Nucleoside Reverse Transcriptase Inhibitor efavirenz.

Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine. Federal Government. Read our disclaimer for details. Last Update Posted : July 29, Study Description. Enrolling subjects will be followed for a total of 12 years.

Detailed Description:. FDA Resources. Arms and Interventions. Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Subjects who have, in previous Sangamo clinical trial received SBT or SBmR-T, autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases, have completed 3 years of post-infusion follow-up, and give consent to participate in the long-term follow-up study.

Exclusion Criteria: There are no exclusion criteria for this study. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.